{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:34:45Z","timestamp":1794044085741,"version":"4.8.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40266-025-01207-3","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:12:34Z","timestamp":1745507554000},"page":"513-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Aging Patient with Cystic Fibrosis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3092-5567","authenticated-orcid":false,"given":"Lauren J.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Mingora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"3","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","volume":"21","author":"J Guo","year":"2022","unstructured":"Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456\u201362.","journal-title":"J Cyst Fibros"},{"issue":"21","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW. Cystic fibrosis: a review. JAMA. 2023;329(21):1859\u201371.","journal-title":"JAMA"},{"key":"1207_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","volume":"74","author":"S Jia","year":"2023","unstructured":"Jia S, Taylor-Cousar JL. Cystic fibrosis modulator therapies. Annu Rev Med. 2023;74:413\u201326.","journal-title":"Annu Rev Med"},{"issue":"19","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"18","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372.","journal-title":"N Engl J Med"},{"issue":"4","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607\u201314.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jcf.2024.10.009","volume":"24","author":"JS Ostrenga","year":"2025","unstructured":"Ostrenga JS, Robinson K, Brown AW, Goss CH, Cromwell EA. Aging with CF: characteristics of people with CF aged 40 and older in the United States. J Cyst Fibros. 2025;24(1):183\u20136.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/thx.2006.060889","volume":"62","author":"CH Goss","year":"2007","unstructured":"Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360\u20137.","journal-title":"Thorax"},{"issue":"4","key":"1207_CR9","first-page":"522","volume":"54","author":"PA Flume","year":"2009","unstructured":"Flume PA, Robinson KA, O\u2019Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522\u201337.","journal-title":"Respir Care"},{"issue":"6","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.25285","volume":"56","author":"ME McGarry","year":"2021","unstructured":"McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496\u2013503.","journal-title":"Pediatr Pulmonol"},{"key":"1207_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106878","volume":"199","author":"M Desai","year":"2022","unstructured":"Desai M, Hine C, Whitehouse JL, Brownlee K, Charman SC, Nagakumar P. Who are the 10%? Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Respir Med. 2022;199: 106878.","journal-title":"Respir Med"},{"issue":"1","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","volume":"10","author":"RVE Dagenais","year":"2020","unstructured":"Dagenais RVE, Su VCH, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med. 2020;10(1):23.","journal-title":"J Clin Med"},{"issue":"4","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","volume":"11","author":"N Mayer-Hamblett","year":"2023","unstructured":"Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023;11(4):329\u201340.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","volume":"21","author":"S Szentpetery","year":"2022","unstructured":"Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022;21(5):777\u201383.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/nu14071341","volume":"14","author":"PN Freswick","year":"2022","unstructured":"Freswick PN, Reid EK, Mascarenhas MR. Pancreatic enzyme replacement therapy in cystic fibrosis. Nutrients. 2022;14(7):1341.","journal-title":"Nutrients"},{"issue":"Suppl 2","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jcf.2017.06.013","volume":"16","author":"JM Abraham","year":"2017","unstructured":"Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40\u20139.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2337\/db22-0949","volume":"72","author":"MS Putman","year":"2023","unstructured":"Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, et al. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes. 2023;72(6):677\u201389.","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R. Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. J Cyst Fibros. 2019;18(Suppl 2):S3-s9.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1207_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","volume":"12","author":"A Kelly","year":"2013","unstructured":"Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318\u201331.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697\u2013708.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"1207_CR21","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","volume":"18","author":"CL Chan","year":"2019","unstructured":"Chan CL, Ode KL, Granados A, Moheet A, Moran A, Hameed S. Continuous glucose monitoring in cystic fibrosis\u2014a practical guide. J Cyst Fibros. 2019;18(Suppl 2):S25-s31.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"1207_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/dom.13544","volume":"21","author":"MC Geyer","year":"2019","unstructured":"Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes Obes Metab. 2019;21(3):700\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1207_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jcf.2024.06.007","volume":"23","author":"A Santhakumar","year":"2024","unstructured":"Santhakumar A, Lewis F, Pickles J, Winterbottom H, Punt S, Beynon J, et al. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: a single centre experience. J Cyst Fibros. 2024;23(5):853\u20136.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1210\/clinem\/dgaa167","volume":"105","author":"H Gnanapragasam","year":"2020","unstructured":"Gnanapragasam H, Mustafa N, Bierbrauer M, Andrea Providence T, Dandona P. Semaglutide in cystic fibrosis-related diabetes. J Clin Endocrinol Metab. 2020;105(7):2341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2337\/dc06-1576","volume":"30","author":"SJ Schwarzenberg","year":"2007","unstructured":"Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30(5):1056\u201361.","journal-title":"Diabetes Care"},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jcf.2024.08.007","volume":"23","author":"DM Goetz","year":"2024","unstructured":"Goetz DM, Brown RF, Filigno SS, Bichl SL, Nelson AL, Merlo CA, et al. Cystic fibrosis foundation position paper: redefining the CF care model. J Cyst Fibros. 2024;23:1055.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","volume":"86","author":"J Paccou","year":"2010","unstructured":"Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2010;86(1):1\u20137.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"1207_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/jc.2004-1629","volume":"90","author":"RM Aris","year":"2005","unstructured":"Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1207_CR29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00198-019-04893-z","volume":"30","author":"E Cairoli","year":"2019","unstructured":"Cairoli E, Eller-Vainicher C, Morlacchi LC, Tarsia P, Rossetti V, Pappalettera M, et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int. 2019;30(6):1255\u201363.","journal-title":"Osteoporos Int"},{"issue":"Suppl 2","key":"1207_CR30","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","volume":"18","author":"A Anabtawi","year":"2019","unstructured":"Anabtawi A, Le T, Putman M, Tangpricha V, Bianchi ML. Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications. J Cyst Fibros. 2019;18(Suppl 2):S48-s55.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"1207_CR31","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359\u201381.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1207_CR32","first-page":"Cd002010","volume":"1","author":"TC Jeffery","year":"2023","unstructured":"Jeffery TC, Chang AB, Conwell LS. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2023;1(1):Cd002010.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1207_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1067\/mpd.2000.107891","volume":"137","author":"BS Zemel","year":"2000","unstructured":"Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr. 2000;137(3):374\u201380.","journal-title":"J Pediatr"},{"issue":"10","key":"1207_CR34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/thorax.56.10.746","volume":"56","author":"R Sharma","year":"2001","unstructured":"Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001;56(10):746\u201350.","journal-title":"Thorax"},{"issue":"5","key":"1207_CR35","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","volume":"108","author":"VA Stallings","year":"2008","unstructured":"Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108(5):832\u20139.","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"1207_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","volume":"19","author":"T Harindhanavudhi","year":"2020","unstructured":"Harindhanavudhi T, Wang Q, Dunitz J, Moran A, Moheet A. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis. J Cyst Fibros. 2020;19(1):139\u201345.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1207_CR37","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/nu14061216","volume":"14","author":"J Bailey","year":"2022","unstructured":"Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients. 2022;14(6):1216.","journal-title":"Nutrients"},{"issue":"6","key":"1207_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcf.2023.08.004","volume":"22","author":"C Greaney","year":"2023","unstructured":"Greaney C, Doyle A, Drummond N, King S, Hollander-Kraaijeveld F, Robinson K, Tierney A. What do people with cystic fibrosis eat? Diet quality, macronutrient and micronutrient intakes (compared to recommended guidelines) in adults with cystic fibrosis-a systematic review. J Cyst Fibros. 2023;22(6):1036\u201347.","journal-title":"J Cyst Fibros"},{"key":"1207_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","volume":"24","author":"GA Ratti","year":"2024","unstructured":"Ratti GA, Smith H, Mirfakhraee S, Reisch J, Cohen L, Jain R, Finklea JD. Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros. 2024;24:47.","journal-title":"J Cyst Fibros"},{"issue":"20","key":"1207_CR40","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023;330(20):2000\u201315.","journal-title":"JAMA"},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","volume":"24","author":"S Park","year":"2024","unstructured":"Park S, Jain R, Mirfakhraee S. Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. J Cyst Fibros. 2024;24:40.","journal-title":"J Cyst Fibros"},{"key":"1207_CR42","unstructured":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050. Lancet. 2024."},{"issue":"11","key":"1207_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029282","volume":"12","author":"ED Michos","year":"2023","unstructured":"Michos ED, Lopez-Jimenez F, Gulati M. Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. J Am Heart Assoc. 2023;12(11): e029282.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"1207_CR44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","volume":"76","author":"J Dana","year":"2022","unstructured":"Dana J, Debray D, Beaufr\u00e8re A, Hillaire S, Fabre M, Reinhold C, et al. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022;76(2):420\u201334.","journal-title":"J Hepatol"},{"issue":"1","key":"1207_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcf.2019.06.004","volume":"19","author":"EM Lowery","year":"2020","unstructured":"Lowery EM, Afshar M, West N, Kovacs EJ, Smith B, Joyce C. Self-reported alcohol use in the cystic fibrosis community. J Cyst Fibros. 2020;19(1):84\u201390.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"1207_CR46","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","volume":"16","author":"DH Leung","year":"2017","unstructured":"Leung DH, Narkewicz MR. Cystic fibrosis-related cirrhosis. J Cyst Fibros. 2017;16(Suppl 2):S50-s61.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"1207_CR47","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","volume":"79","author":"ZM Sellers","year":"2024","unstructured":"Sellers ZM, Assis DN, Paranjape SM, Sathe M, Bodewes F, Bowen M, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2024;79(5):1220\u201338.","journal-title":"Hepatology"},{"issue":"9","key":"1207_CR48","first-page":"Cd000222","volume":"9","author":"K Cheng","year":"2017","unstructured":"Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2017;9(9):Cd000222.","journal-title":"Cochrane Database Syst Rev"},{"key":"1207_CR49","first-page":"54","volume":"50","author":"JA Eldredge","year":"2024","unstructured":"Eldredge JA, Oliver MR, Ooi CY. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Paediatr Respir Rev. 2024;50:54\u201361.","journal-title":"Paediatr Respir Rev"},{"issue":"10","key":"1207_CR50","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","volume":"11","author":"PJ Mogayzel Jr","year":"2014","unstructured":"Mogayzel PJ Jr, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640\u201350.","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"1207_CR51","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","volume":"187","author":"PJ Mogayzel Jr","year":"2013","unstructured":"Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1207_CR52","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"1207_CR53","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","volume":"71","author":"RA Floto","year":"2016","unstructured":"Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(Suppl 1):i1-22.","journal-title":"Thorax"},{"issue":"5","key":"1207_CR54","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jcf.2023.04.002","volume":"22","author":"J Madaule","year":"2023","unstructured":"Madaule J, Valenzuela F, Mittaine M, Gallois Y, Baladi B, Murris M, et al. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. J Cyst Fibros. 2023;22(5):944\u20138.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"1207_CR55","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/alr.22974","volume":"12","author":"AJ Kimple","year":"2022","unstructured":"Kimple AJ, Senior BA, Naureckas ET, Gudis DA, Meyer T, Hempstead SE, et al. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol. 2022;12(9):1089\u2013103.","journal-title":"Int Forum Allergy Rhinol."},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-443-18649-3.00017-3","volume-title":"Therapeutic drug monitoring","author":"AL Pyle-Eilola","year":"2024","unstructured":"Pyle-Eilola AL. Chapter 8\u2014guidelines for monitoring vancomycin, aminoglycosides, and other antibiotics. In: Dasgupta A, editor. Therapeutic drug monitoring. 2nd ed. New York: Academic Press; 2024. p. 197\u2013215.","edition":"2"},{"issue":"2","key":"1207_CR57","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jcf.2020.11.020","volume":"20","author":"EE Harruff","year":"2021","unstructured":"Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, et al. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: ototoxicity following tobramycin treatment. J Cyst Fibros. 2021;20(2):288\u201394.","journal-title":"J Cyst Fibros"},{"key":"1207_CR58","unstructured":"Cystic Fibrosis Foundation Patient Registry. Bethesda, Maryland: \u00a92024 Cystic Fibrosis Foundation; 2023."},{"issue":"2","key":"1207_CR59","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcf.2020.08.002","volume":"20","author":"EC Elson","year":"2021","unstructured":"Elson EC, Meier E, Oermann CM. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis. J Cyst Fibros. 2021;20(2):284\u20137.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"1207_CR60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0194599818782444","volume":"159","author":"EM Zettner","year":"2018","unstructured":"Zettner EM, Gleser MA. Progressive hearing loss among patients with cystic fibrosis and parenteral aminoglycoside treatment. Otolaryngol Head Neck Surg. 2018;159(5):887\u201394.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"12","key":"1207_CR61","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/phar.2478","volume":"40","author":"HG Rizk","year":"2020","unstructured":"Rizk HG, Lee JA, Liu YF, Endriukaitis L, Isaac JL, Bullington WM. Drug-induced ototoxicity: a comprehensive review and reference guide. Pharmacotherapy. 2020;40(12):1265\u201375.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1207_CR62","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","volume":"22","author":"D Purkayastha","year":"2023","unstructured":"Purkayastha D, Agtarap K, Wong K, Pereira O, Co J, Pakhale S, Kanji S. Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae. J Cyst Fibros. 2023;22(3):478\u201383.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1207_CR63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jcpt.13329","volume":"46","author":"EM Gavioli","year":"2021","unstructured":"Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators. J Clin Pharm Ther. 2021;46(2):286\u201394.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1207_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jcf.2017.04.014","volume":"17","author":"TL May","year":"2018","unstructured":"May TL, Gifford AH, Lahiri T, Black A, Trang J, Cornell AG, et al. Complications of long and intermediate term venous catheters in cystic fibrosis patients: a multicenter study. J Cyst Fibros. 2018;17(1):96\u2013104.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"1207_CR65","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1513\/AnnalsATS.201404-175OC","volume":"11","author":"JD Mermis","year":"2014","unstructured":"Mermis JD, Strom JC, Greenwood JP, Low DM, He J, Stites SW, Simpson SQ. Quality improvement initiative to reduce deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibrosis. Ann Am Thorac Soc. 2014;11(9):1404\u201310.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"1207_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5301\/jva.5000347","volume":"16","author":"C Dupont","year":"2015","unstructured":"Dupont C, Gouya H, Panzo R, Hubert D, Correas JM, Agrario L, et al. Complications of peripherally inserted central catheters in adults with cystic fibrosis or bronchiectasis. J Vasc Access. 2015;16(3):245\u20139.","journal-title":"J Vasc Access"},{"issue":"3","key":"1207_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.chest.2023.03.043","volume":"164","author":"AH Gifford","year":"2023","unstructured":"Gifford AH, Hinton AC, Jia S, Nasr SZ, Mermis JD, Lahiri T, et al. Complications and practice variation in the use of peripherally inserted central venous catheters in people with cystic fibrosis: the Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study. Chest. 2023;164(3):614\u201324.","journal-title":"Chest"},{"issue":"4","key":"1207_CR68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","volume":"18","author":"M Shteinberg","year":"2019","unstructured":"Shteinberg M, Lulu AB, Downey DG, Blumenfeld Z, Rousset-Jablonski C, Perceval M, et al. Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. J Cyst Fibros. 2019;18(4):525\u20139.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"1207_CR69","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.jcf.2019.08.024","volume":"18","author":"KS Hughan","year":"2019","unstructured":"Hughan KS, Daley T, Rayas MS, Kelly A, Roe A. Female reproductive health in cystic fibrosis. J Cyst Fibros. 2019;18(Suppl 2):S95-s104.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"1207_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","volume":"21","author":"R Jain","year":"2022","unstructured":"Jain R, Kazmerski TM, Zuckerwise LC, West NE, Montemayor K, Aitken ML, et al. Pregnancy in cystic fibrosis: review of the literature and expert recommendations. J Cyst Fibros. 2022;21(3):387\u201395.","journal-title":"J Cyst Fibros"},{"key":"1207_CR71","doi-asserted-by":"crossref","unstructured":"Jain R, Magaret A, Vu PT, VanDalfsen JM, Keller A, Wilson A, et al. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022;9(1).","DOI":"10.1136\/bmjresp-2022-001289"},{"issue":"2","key":"1207_CR72","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0005-2022","volume":"18","author":"K Montemayor","year":"2022","unstructured":"Montemayor K, Tullis E, Jain R, Taylor-Cousar JL. Management of pregnancy in cystic fibrosis. Breathe (Sheff). 2022;18(2): 220005.","journal-title":"Breathe (Sheff)"},{"issue":"12","key":"1207_CR73","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/ppul.26706","volume":"58","author":"J Elijah","year":"2023","unstructured":"Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 1: pregnancy and lactation. Pediatr Pulmonol. 2023;58(12):3377\u201385.","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 2","key":"1207_CR74","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.jcf.2019.08.007","volume":"18","author":"JC Yoon","year":"2019","unstructured":"Yoon JC, Casella JL, Litvin M, Dobs AS. Male reproductive health in cystic fibrosis. J Cyst Fibros. 2019;18(Suppl 2):S105\u201310.","journal-title":"J Cyst Fibros"},{"issue":"Suppl 1","key":"1207_CR75","first-page":"S75","volume":"57","author":"TM Kazmerski","year":"2022","unstructured":"Kazmerski TM, West NE, Jain R, Uluer A, Georgiopoulos AM, Aitken ML, Taylor-Cousar JL. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022;57(Suppl 1):S75-s88.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"1207_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101855","volume":"38","author":"C Gatenby","year":"2024","unstructured":"Gatenby C, Simpson P. Menopause: physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024;38(1): 101855.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"1207_CR77","first-page":"401","volume":"30","author":"K Prochownik","year":"2023","unstructured":"Prochownik K, Jain R, Taylor-Cousar JL, Lavage DR, Stransky OM, Thomas HN, Kazmerski TM. Menopause in people with cystic fibrosis. Menopause. 2023;30(4):401\u20135.","journal-title":"Menopause"},{"issue":"12","key":"1207_CR78","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/ijc.24679","volume":"125","author":"M Johannesson","year":"2009","unstructured":"Johannesson M, Askling J, Montgomery SM, Ekbom A, Bahmanyar S. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer. 2009;125(12):2953\u20136.","journal-title":"Int J Cancer"},{"issue":"2","key":"1207_CR79","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jnci\/djs481","volume":"105","author":"P Maisonneuve","year":"2013","unstructured":"Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1207_CR80","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0022-3476(05)80296-3","volume":"119","author":"JP Neglia","year":"1991","unstructured":"Neglia JP, Wielinski CL, Warwick WJ. Cancer risk among patients with cystic fibrosis. J Pediatr. 1991;119(5):764\u20136.","journal-title":"J Pediatr"},{"issue":"3","key":"1207_CR81","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","volume":"154","author":"D Hadjiliadis","year":"2018","unstructured":"Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736-45.e14.","journal-title":"Gastroenterology"},{"issue":"9","key":"1207_CR82","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4251\/wjgo.v13.i9.1121","volume":"13","author":"B Hoskins","year":"2021","unstructured":"Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W. Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis. World J Gastrointest Oncol. 2021;13(9):1121\u201331.","journal-title":"World J Gastrointest Oncol."},{"issue":"5","key":"1207_CR83","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jnci\/95.5.381","volume":"95","author":"P Maisonneuve","year":"2003","unstructured":"Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95(5):381\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"1207_CR84","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejogrb.2017.12.005","volume":"221","author":"C Rousset-Jablonski","year":"2018","unstructured":"Rousset-Jablonski C, Reynaud Q, Nove-Josserand R, Ray-Coquard I, Mekki Y, Golfier F, Durieu I. High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. Eur J Obstet Gynecol Reprod Biol. 2018;221:40\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"1207_CR85","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/thoraxjnl-2021-218461","volume":"77","author":"C Thornton","year":"2022","unstructured":"Thornton C, Somayaji R, Chu A, Parkins MD. Human papillomavirus (HPV) and cervical dysplasia in adult female cystic fibrosis (CF) lung transplant recipients. Thorax. 2022;77(6):625\u20137.","journal-title":"Thorax"},{"issue":"3","key":"1207_CR86","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jcf.2022.11.005","volume":"22","author":"C Rousset-Jablonski","year":"2023","unstructured":"Rousset-Jablonski C, Mekki Y, Denis A, Reynaud Q, Nove-Josserand R, Durupt S, et al. Human papillomavirus prevalence, persistence and cervical dysplasia in females with cystic fibrosis. J Cyst Fibros. 2023;22(3):505\u201314.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1207_CR87","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.chest.2021.09.003","volume":"161","author":"P Maisonneuve","year":"2022","unstructured":"Maisonneuve P, Lowenfels AB. Cancer in cystic fibrosis: a narrative review of prevalence, risk factors, screening, and treatment challenges: adult cystic fibrosis series. Chest. 2022;161(2):356\u201364.","journal-title":"Chest"},{"issue":"4","key":"1207_CR88","doi-asserted-by":"publisher","first-page":"2300174","DOI":"10.1183\/13993003.00174-2023","volume":"62","author":"F Frost","year":"2023","unstructured":"Frost F, Nazareth D, Fauchier L, Wat D, Shelley J, Austin P, et al. Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study. Eur Respir J. 2023;62(4):2300174.","journal-title":"Eur Respir J"},{"issue":"6","key":"1207_CR89","doi-asserted-by":"publisher","first-page":"806","DOI":"10.7326\/0003-4819-82-6-806","volume":"82","author":"J Lieberman","year":"1975","unstructured":"Lieberman J, Rodbard S. Low blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat? Ann Intern Med. 1975;82(6):806\u20138.","journal-title":"Ann Intern Med"},{"issue":"620","key":"1207_CR90","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0140-6736(69)90263-3","volume":"2","author":"HB Valman","year":"1969","unstructured":"Valman HB, France NE. The vas deferens in cystic fibrosis. Lancet. 1969;2(620):566\u20137.","journal-title":"Lancet"},{"issue":"5","key":"1207_CR91","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","volume":"21","author":"A Gramegna","year":"2022","unstructured":"Gramegna A, De Petro C, Leonardi G, Contarini M, Amati F, Meazza R, et al. Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: a case series. J Cyst Fibros. 2022;21(5):885\u20137.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1207_CR92","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","volume":"75","author":"V Figueroa","year":"2002","unstructured":"Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr. 2002;75(6):1005\u201311.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1207_CR93","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265\u201371.","journal-title":"J Cyst Fibros"},{"key":"1207_CR94","unstructured":"Screening for lipid disorders in adults: recommendation statement. Am Fam Physician. 2009;80(11):1273\u20134."},{"issue":"8","key":"1207_CR95","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik M. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328(8):754\u201371.","journal-title":"JAMA"},{"issue":"2","key":"1207_CR96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jcf.2021.08.011","volume":"21","author":"V Leso","year":"2022","unstructured":"Leso V, Romano R, Santocono C, Caruso M, Iacotucci P, Carnovale V, Iavicoli I. The impact of cystic fibrosis on the working life of patients: a systematic review. J Cyst Fibros. 2022;21(2):361\u20139.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1207_CR97","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/occmed\/kqt140","volume":"64","author":"K Targett","year":"2014","unstructured":"Targett K, Bourke S, Nash E, Murphy E, Ayres J, Devereux G. Employment in adults with cystic fibrosis. Occup Med (Lond). 2014;64(2):87\u201394.","journal-title":"Occup Med (Lond)"},{"issue":"1","key":"1207_CR98","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1086\/646419","volume":"13","author":"NJ Ehrenkranz","year":"1992","unstructured":"Ehrenkranz NJ, Nerenberg DE, Shultz JM, Slater KC. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol. 1992;13(1):21\u201332.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"1207_CR99","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","volume":"23","author":"A Gramegna","year":"2024","unstructured":"Gramegna A, Addy C, Allen L, Bakkeheim E, Brown C, Daniels T, et al. Standards for the care of people with cystic fibrosis (CF); planning for a longer life. J Cyst Fibros. 2024;23(3):375\u201387.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1207_CR100","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jcf.2024.09.011","volume":"23","author":"RF Brown","year":"2024","unstructured":"Brown RF, Close CT, Mailes MG, Gonzalez LJ, Goetz DM, Filigno SS, et al. Cystic fibrosis foundation position paper: redefining the cystic fibrosis care team. J Cyst Fibros. 2024;23(6):1045\u201354.","journal-title":"J Cyst Fibros"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01207-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01207-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01207-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:03:07Z","timestamp":1749510187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01207-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01207-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"31 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by the Carolinas Consortium. Dr. Flume is supported, in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under grant no. UL1 TR001450. Dr. Sullivan receives funding from the Cystic Fibrosis Foundation. Dr. Mingora receives funding from the Cystic Fibrosis Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Flume has grant support from Boeringher-Ingelheim, Cystic Fibrosis Foundation Therapeutics, National Institutes of Health, and Vertex Pharmaceuticals, Inc, and provides consultation to Sionna and Vertex Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed substantially to the writing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}